References
- Wang J, Zhan P, Ouyang J, Chen B, Zhou R. Prophylactic use of granulocyte colony-stimulating factor after induction chemotherapy in patients with newly diagnosed acute myeloid leukemia may increase the complete remission rate: a meta-analysis of five randomised controlled trials. Leuk Lymphoma 2009; 50: 457–459
- Bhalla K, Holladay C, Arlin Z, Grant S, Ibrado A M, Jasiok M. Treatment with interleukin-3 plus granulocyte-macrophage colony-stimulating factors improves the selectivity of Ara-C in vitro against acute myeloid leukemia blasts. Blood 1991; 78: 2674–2679
- de Figueiredo L L, de Abreu e Lima R S, Rego E M. Granulocyte colony-stimulating factor and leukemogenesis. Mediators Inflamm 2004; 13: 145–150
- Zeng Z, Shi Y X, Samudio I J, Wang R Y, Ling X, Frolova O, et al. Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML. Blood 2008, [Epub ahead of print]
- Nervi B, Rairez P, Rettig M P, Uy M S, Holt M S, Ritchey J K, et al. Chemosensitization of AML following mobilization by CXCR4 antagonist AMD 3100. Blood 2008, [Epub ahead of print]
- Tavor S Eisenbach M, Jacob-Hirsch J, Golan T, Petit I, Ben-Zion K, et al. The CXCR4 antagonist AMD 3100 impairs survival of human AML cells and induces their differentiation. Leukemia 2008; 22: 2151–2158